MedTrace Logo

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

NCT04962425 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2021-07-15

No results posted yet for this study

Summary

According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction model for TRC.

Conditions

Interventions

DRUG

Trastuzumab

Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-08
Primary Completion
2021-06-01
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04962425 on ClinicalTrials.gov